How to buy Eli Lilly and Company shares in Australia

Eli Lilly and Company (LLY) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$762.73. During the previous open market day, the price has varied from a low of USD755.56 to a high of USD786. Eli Lilly and Company is listed on the NYSE. All prices are listed in US Dollars.

Have Eli Lilly and Company's shares ever split?

Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.

Eli Lilly and Company shares at a glance

52-week range	US$675.705 - US$967.2689
50-day moving average more info button	US$777.0028
200-day moving average more info button	US$824.6084
Target price	US$951.9752
PE ratio more info button	63.72
Dividend yield more info button	US$5.4 (0.76%)
Earnings per share (TTM) more info button	US$12.32

Eli Lilly and Company share growth calculator

Investment amount

US$

Investment period Choose a point in time from the list 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago 2 years ago 3 years ago 5 years ago

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Eli Lilly and Company price performance over time

Historical closes compared with the last close of $762.73

Compare trading platforms to buy Eli Lilly and Company shares

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Eli Lilly and Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is it worth buying Eli Lilly and Company stock?

Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eli Lilly and Company's P/E ratio

Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 64x. In other words, Eli Lilly and Company shares trade at around 64x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Eli Lilly and Company's PEG ratio

Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2038. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Eli Lilly and Company's EBITDA

Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$22 billion (£17.4 billion).

The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure stock profitability.

Eli Lilly and Company share price volatility

Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as US$675.705 up to US$967.2689. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.394. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).

Eli Lilly and Company financials

Revenue TTM	US$49 billion
Operating margin TTM	42.49%
Gross profit TTM	US$40 billion
Return on assets TTM	16.45%
Return on equity TTM	77.28%
Profit margin	22.67%
Book value	16.635
Market capitalisation more info button	US$704.7 billion
EBITDA more info button	US$22 billion

TTM: trailing 12 months

Eli Lilly and Company share dividends

Dividend payout ratio: 40.7% of net profits

Recently Eli Lilly and Company has paid out, on average, around 40.7% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.76% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0.76% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $5.4 per share.

While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that Eli Lilly and Company may be investing much of the rest of its net profits in future growth.

Eli Lilly and Company's most recent dividend payout was on 9 June 2025. The latest dividend was paid out to all shareholders who bought their shares by 15 May 2025 (the "ex-dividend date").

Eli Lilly and Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Eli Lilly and Company's total ESG risk score

Total ESG risk: 32.36

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 12/31/2018) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Eli Lilly and Company's environmental score

Environmental score: 0.63/100

Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Eli Lilly and Company's social score

Social score: 16.68/100

Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Eli Lilly and Company's governance score

Governance score: 13.31/100

Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Eli Lilly and Company's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Eli Lilly and Company was last rated for ESG on: 2019-01-01.

Total ESG score	32.36
Total ESG percentile	70.22
Environmental score	0.63
Environmental score percentile	1
Social score	16.68
Social score percentile	1
Governance score	13.31
Governance score percentile	1
Level of controversy	3

Eli Lilly and Company overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Frequently asked questions

• What percentage of Eli Lilly and Company is owned by insiders or institutions?

  Currently 0.163% of Eli Lilly and Company shares are held by insiders and 84.069% by institutions.

• When does the fiscal year end for Eli Lilly and Company?

  Eli Lilly and Company's fiscal year ends in December.

• Where is Eli Lilly and Company based?

  Eli Lilly and Company's address is: Lilly Corporate Center, Indianapolis, IN, United States, 46285

• What is Eli Lilly and Company's ISIN number?

  Eli Lilly and Company's international securities identification number is: US5324571083

• What is Eli Lilly and Company's CUSIP number?

  Eli Lilly and Company's Committee on Uniform Securities Identification Procedures number is: 532457108